Geller Family Office Services Has Lifted Its Acelrx Pharmaceuticals (ACRX) Holding; Meiji Yasuda Life Insurance Company Boosted Monsanto Co New (MON) Position

April 26, 2018 - By Richard Conner

Monsanto Company (NYSE:MON) Logo

Geller Family Office Services Llc increased its stake in Acelrx Pharmaceuticals Inc (ACRX) by 175% based on its latest 2017Q4 regulatory filing with the SEC. Geller Family Office Services Llc bought 175,000 shares as the company’s stock rose 6.02% while stock markets declined. The institutional investor held 275,000 shares of the health care company at the end of 2017Q4, valued at $557,000, up from 100,000 at the end of the previous reported quarter. Geller Family Office Services Llc who had been investing in Acelrx Pharmaceuticals Inc for a number of months, seems to be bullish on the $119.61M market cap company. It closed at $2.35 lastly. It is down 27.87% since April 26, 2017 and is downtrending. It has underperformed by 39.42% the S&P500.

Meiji Yasuda Life Insurance Company increased its stake in Monsanto Co New (MON) by 15.66% based on its latest 2017Q4 regulatory filing with the SEC. Meiji Yasuda Life Insurance Company bought 2,752 shares as the company’s stock rose 1.12% while stock markets declined. The institutional investor held 20,322 shares of the agricultural chemicals company at the end of 2017Q4, valued at $2.37 million, up from 17,570 at the end of the previous reported quarter. Meiji Yasuda Life Insurance Company who had been investing in Monsanto Co New for a number of months, seems to be bullish on the $55.02B market cap company. The stock decreased 0.05% or $0.06 during the last trading session, reaching $124.68. About 2.68 million shares traded. Monsanto Company (NYSE:MON) has risen 3.06% since April 26, 2017 and is uptrending. It has underperformed by 8.49% the S&P500.

Investors sentiment increased to 0.83 in 2017 Q4. Its up 0.13, from 0.7 in 2017Q3. It improved, as 8 investors sold ACRX shares while 15 reduced holdings. 7 funds opened positions while 12 raised stakes. 4.57 million shares or 31.27% less from 6.65 million shares in 2017Q3 were reported. Morgan Stanley holds 17,537 shares. Geode Capital Management Ltd Llc owns 215,834 shares or 0% of their US portfolio. Joel Isaacson & Communication Ltd accumulated 0.02% or 70,000 shares. Da Davidson And Commerce owns 63,500 shares. State Street Corp holds 39,856 shares or 0% of its portfolio. Geller Family Office Serv holds 0.28% or 275,000 shares in its portfolio. Citadel Advsr Ltd Liability Corporation accumulated 0% or 155,158 shares. Northern Tru has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Barclays Plc owns 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 904 shares. Bnp Paribas Arbitrage Sa stated it has 8 shares. Virtu Fincl has 0.01% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Goldman Sachs Group holds 0% or 14,992 shares in its portfolio. Art Advsr Lc holds 0.01% or 137,398 shares in its portfolio. Wells Fargo Mn accumulated 30,495 shares. Susquehanna Int Ltd Liability Partnership holds 0% or 164,137 shares.

Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 21 analyst reports since August 4, 2015 according to SRatingsIntel. Seaport Global upgraded AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Friday, May 6 to “Buy” rating. Jefferies maintained it with “Hold” rating and $2.25 target in Friday, March 9 report. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has “Hold” rating given on Tuesday, August 1 by Cowen & Co. Roth Capital maintained it with “Buy” rating and $10.50 target in Monday, October 5 report. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has “Buy” rating given on Friday, October 30 by Jefferies. TH Capital maintained it with “Buy” rating and $10.50 target in Monday, October 5 report. The firm has “Hold” rating by Piper Jaffray given on Tuesday, July 25. The firm has “Hold” rating by Piper Jaffray given on Thursday, October 12. The firm has “Hold” rating given on Tuesday, August 4 by Cowen & Co. On Friday, July 14 the stock rating was maintained by Jefferies with “Buy”.

Investors sentiment decreased to 0.81 in 2017 Q4. Its down 0.03, from 0.84 in 2017Q3. It turned negative, as 69 investors sold MON shares while 328 reduced holdings. 75 funds opened positions while 246 raised stakes. 317.44 million shares or 1.24% less from 321.42 million shares in 2017Q3 were reported. Capstone Investment Limited stated it has 0.49% of its portfolio in Monsanto Company (NYSE:MON). Primecap Mgmt Co Ca invested 0.98% of its portfolio in Monsanto Company (NYSE:MON). Markel Corp has 396,700 shares for 0.87% of their portfolio. Prelude Capital Mngmt Limited Liability Company holds 2.32% of its portfolio in Monsanto Company (NYSE:MON) for 247,258 shares. Registered Invest Advisor Incorporated owns 3,358 shares. Cap Intll Ltd Ca owns 16,400 shares. Nomura Asset Limited invested 0.13% in Monsanto Company (NYSE:MON). Highland Management LP accumulated 0.1% or 18,100 shares. Alpine Management owns 1.87 million shares. Mason Street Advsr Ltd Co holds 0.17% or 61,194 shares in its portfolio. Northern Tru accumulated 0.22% or 7.32 million shares. Bb&T Securities Lc has 12,821 shares. Weatherly Asset Management Lp invested in 8,204 shares or 0.23% of the stock. Cadence National Bank & Trust Na invested 0.08% in Monsanto Company (NYSE:MON). Oz Management Ltd Partnership has invested 0.88% in Monsanto Company (NYSE:MON).

Since January 9, 2018, it had 0 insider purchases, and 1 insider sale for $966,720 activity.

Meiji Yasuda Life Insurance Company, which manages about $725.50 million US Long portfolio, decreased its stake in Ametek Inc New (NYSE:AME) by 6,913 shares to 28,072 shares, valued at $2.03 million in 2017Q4, according to the filing. It also reduced its holding in Zoetis Inc (NYSE:ZTS) by 5,400 shares in the quarter, leaving it with 13,900 shares, and cut its stake in Apple Inc (NASDAQ:AAPL).

Among 23 analysts covering Monsanto Company (NYSE:MON), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Monsanto Company had 63 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by Citigroup on Monday, August 22 with “Neutral”. The firm has “Mkt Perform” rating given on Monday, September 26 by Bernstein. The firm earned “Neutral” rating on Tuesday, June 27 by Susquehanna. Jefferies downgraded the shares of MON in report on Wednesday, July 12 to “Hold” rating. RBC Capital Markets maintained Monsanto Company (NYSE:MON) on Tuesday, August 1 with “Hold” rating. The firm earned “Sector Perform” rating on Thursday, June 29 by RBC Capital Markets. The stock has “Equal Weight” rating by Barclays Capital on Thursday, January 7. The stock of Monsanto Company (NYSE:MON) has “Overweight” rating given on Tuesday, December 1 by Atlantic Securities. On Friday, September 11 the stock rating was initiated by Bernstein with “Underperform”. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, August 27 report.

Monsanto Company (NYSE:MON) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts